Connect with us

Heartland

CBD 2020: What to Expect + Our Top Predictions

CBD 2020: What to Expect + Our Top Predictions by Aaron Cadena at CBD Origin

With 2020 just around the corner, there’s an exciting year ahead! Here’s what to expect in the upcoming year + our top predictions for CBD 2020!

CBD Origin is the premier source for CBD knowledge and information. Find informative articles, helpful guides, the latest news, and more at CBDOrigin.com

Republished by Plato

Published

on

Over the last decade the CBD market has made some huge strides forward, but, in 2019, the market has exploded.

From 2015 to 2018, Cannabidiol (CBD) product sales in the US grew an estimated 300% from  $200 million to $620 million. This year, CBD sales in the US are estimated to reach a whopping $5 billion, according to a recent Brightfield Group industry analysis report.

Compared to the $200 million of sales in 2015, that’s over 2500% growth!

While the growth of the CBD market in 2019 is beyond ridiculous, experts believe that CBD sales will continue to skyrocket and reach $25 billion by 2025.

With 2020 just around the corner, here’s what we expect will happen in the CBD industry during this upcoming year.

Cannabis Legalization in 2020

Last year, hemp-derived CBD was federally legalized under the 2018 Agricultural Improvement Act; however, unclear laws have kept CBD intertwined with the legal complications of Cannabis in some states. Because of this, it’s important to also stay up to date on cannabis legalization laws overall.

From 1996 to the present day, 33 states have legalized cannabis for medical use, and 11 of those states have legalized cannabis for recreational adult use. In the remaining 17 states, cannabis remains fully illegal in 11 states and decriminalized in 3 of those 11 states. In the remaining states, the legal status is mixed or unclear

2020 will be a major voting year, and as the end of 2019 draws near, 6 states are actively pushing to get recreational cannabis legalization initiatives onto the ballot.

[adsforwp id=”31857″]

New York: No longer under the heat as the first legislature to tax and regulate cannabis, NY may likely feel more comfortable about voting, yes and the struggle to achieve cannabis legalization in New York will finally end.

New Mexico: On January 21, a legislative session to legalize recreational cannabis use will begin and last just 30-days. With substantial support from Gov. Grisham, New Mexico is positioned to legalize recreational cannabis use; however, many are hesitant to get their hopes up since a similar legislative session in 2019 died in the Senate after passing the House.

New Jersey: Last Monday, on December 16, the New Jersey Marijuana Legalization Amendment reached the number of required signatures and was passed and placed on the ballot. With over 62% of New Jersey residents in support of legalization, according to a recent survey from Monmouth University, combined with the major tax incentives gained by legalization, Recreational Cannabis legalization in the Garden State is a high possibility.

Arizona: Arizona is on track to reach the 237,645 required signatures by the July 2, 2020 deadline and will likely appear on the November 2020 ballot. As the second attempt at legalization, following a narrow disapproval in 2016, and with clear tax incentives, legalizing recreational cannabis is the logical choice for Arizona with a high chance of getting passed.

[adsforwp id=”31857″]

Arkansas: Arkansas is on track to reach the 89,151 required signatures and will likely appear on the November 2020 ballot; however as a Republican-dominant state, the Arkansas Marijuana Legalization Initiative may not get the support it needs.

Florida: It is highly unlikely that the Florida Marijuana Legalization Initiative will reach the 766,200 required signatures by February 2020 and will likely not appear on the 2020 ballot

Missouri: While Missouri may still appear on the ballot if the legalization initiative reaches 160,199 signatures by May 3, 2020, Missouri voters’ support for legalization is very unclear.

South Dakota: South Dakota did not receive enough signatures to get put on the ballot in 2020.

Ohio: Ohio did not receive enough signatures to get put on the ballot in 2020.

Idaho: Idaho is on track to reach required 55,057 signatures by May 2020 and will likely get put on the ballot by November 2020.

Consumers Will Demand for Higher Lab Testing Standards and Increased Transparency from Companies

Due to a lack of consumer awareness and CBD regulations, there has been little pressure on brands to properly and thoroughly test their products. As a result, many brands will only test one out of every thousand or more units for just cannabinoid potency. This is the bare minimum of cannabis testing that will not detect a majority of the harmful compounds that can be found in cannabis-derived products and will not ensure the product is safe or pure.

As consumers become more informed about CBD, they are becoming more aware of the importance and scope of lab testing. Soon, there will be a demand for higher standards and more transparency and possibly laws regulating the production and testing of CBD products.

Diverse Phytocannabinoid-Rich and Terpenoid-Rich Blends Will Get More Attention

In addition to higher standards for lab testing, consumers are also now becoming more aware of the many other cannabinoids and the compounding effect that occurs from using multiple cannabinoids known as the Entourage Effect

This will lead to a higher demand for diverse cannabinoid-rich and terpenoid-rich CBD blends, which brands like Joy Organics, had predicted earlier and have already introduced a variety of cannabinoid-rich blends into their products.

Industrialization and Innovations Will Lead to New CBD Consumption Methods

In addition to diversified CBD blends, as the industry continues to develop, innovation and increased market competition will lead to the development of new ways to use CBD.

Through product diversification, brands will offer more value and features to their products. This will lead to the development of new vertical and horizontal markets that will continue to bolster the growth of the CBD industry.

Consumers Will Catch On to Unethical Business Practices

In the early stages of the CBD industry, and still, even now, there were a lot of unknown variables. Because of this, it was difficult, and even impossible, to set proper guidelines to regulate the industry as it continued to grow.

While many brands operated with integrity and maintained ethical business practices even when no one was looking, there were, and still are, many others who took advantage of the situation.

From inadequate lab testing and photo-shopped lab reports to inaccurate product labels and shady marketing tactics, unethical business behavior has been rampant due to the lack of regulatory guidelines and consumer awareness.

Now that consumers are more educated and continuing to learn more, unethical practices are beginning to be brought to light.

Increased Involvement from Major Brands and Retailers

Estimated to reach a market valuation of more than $25 billion by 2025, the CBD market is one of the biggest opportunities of the decade. Of course, this has gained the attention of major brands and big-box retailers like Walmart, Amazon, and Whole Foods.

While the products offered by these mega-brands seem modest, in 2020, these brands will use their full resources to unleash a massive presence in the CBD industry.

Are You Ready for 2020?

While 2019 was off to a slow start, it’s ending much quicker than it began. In a few days, it’ll be Christmas and before you know it, the new year will begin. Based on the trends we’ve seen, there’s a lot in store for 2020 and we’re ready to take it head-on.

Do you have any predictions or insights to add to the list or any comments to add? Share your insights in the comments below, we’d love to hear from you.

Thanks for joining us and making 2019 an amazing year!

Source: https://cbdorigin.com/cbd-2020/

Heartland

The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology

Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects,…

Republished by Plato

Published

on

Cannabinoids are a group of chemicals that bind to receptors in the human body and, in turn, modulate the endocannabinoid system (ECS). They can be endogenously produced, synthetic, or derived from the plant Cannabis sativa L. Research over the past several decades has shown that the ECS is a cellular communication network essential to maintain multiple biological functions and the homeostasis of the body. Indeed, cannabinoids have been shown to influence a wide variety of biological effects, including memory, pain, reproduction, bone remodeling or immunity, to name a few. Unsurprisingly, given these broad physiological effects, alterations of the ECS have been found in different diseases, including cancer. In recent years, the medical use of cannabis has been approved in different countries for a variety of human conditions. However, the use of these compounds, specifically as anticancer agents, remains controversial. Studies have shown that cannabinoids do have anticancer activity in different tumor types such as breast cancer, melanoma, lymphoma and adult brain cancer. Specifically, phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) has been shown to induce apoptosis and inhibit proliferation of adult cancer cells, as well as modulate angiogenesis and metastasis. Despite increasing evidence that cannabinoids elicit antitumor effects in adult cancers, there is minimal data available on their effects in children or in pediatric cancers despite public and clinical demand for information. Here we describe a comprehensive and critical review of what is known about the effects of cannabinoids on pediatric cancers, highlight current gaps in knowledge and identify the critical issues that need addressing before considering these promising but controversial drugs for use in pediatric oncology.

Keywords: CBD; THC; cannabidiol; cannabinoid; childhood cancer; medical cannabis; pediatric oncology; Δ9-tetrahydrocannabinol.

Source: https://pubmed.ncbi.nlm.nih.gov/33466435/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zmroqAMnEquTZFTfdGx1V1gPEavo-Be3-FKTecJpOlB7LykCL&fc=20200804213506&ff=20210120135252&v=2.14.2

Continue Reading

Heartland

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been…

Republished by Plato

Published

on

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood-brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.

Keywords: Cannabis; multitarget; phytocannabinoids (THC and CBD); receptors; terpenes.

Source: https://pubmed.ncbi.nlm.nih.gov/33466734/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zmroqAMnEquTZFTfdGx1V1gPEavo-Be3-FKTecJpOlB7LykCL&fc=20200804213506&ff=20210120135252&v=2.14.2

Continue Reading

Heartland

Pervasive cropland in protected areas highlight trade-offs between conservation and food security

Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use…

Republished by Plato

Published

on

. 2021 Jan 26;118(4):e2010121118.

doi: 10.1073/pnas.2010121118.

Affiliations

Item in Clipboard

Varsha Vijay et al. Proc Natl Acad Sci U S A. .

Abstract

Global cropland expansion over the last century caused widespread habitat loss and degradation. Establishment of protected areas aims to counteract the loss of habitats and to slow species extinctions. However, many protected areas also include high levels of habitat disturbance and conversion for uses such as cropland. Understanding where and why this occurs may realign conservation priorities and inform protected area policy in light of competing priorities such as food security. Here, we use our global synthesis cropland dataset to quantify cropland in protected areas globally and assess their relationship to conservation aims and socio-environmental context. We estimate that cropland occupies 1.4 million km2 or 6% of global protected area. Cropland occurs across all protected area management types, with 22% occurring in strictly protected areas. Cropland inside protected areas is more prevalent in countries with higher population density, lower income inequality, and with higher agricultural suitability of protected lands. While this phenomenon is dominant in midnorthern latitudes, areas of cropland in protected areas of the tropics and subtropics may present greater trade-offs due to higher levels of both biodiversity and food insecurity. Although area-based targets are prominent in biodiversity goal-setting, our results show that they can mask persistent anthropogenic land uses detrimental to native ecosystem conservation. To ensure the long-term efficacy of protected areas, post-2020 goal setting must link aims for biodiversity and human health and improve monitoring of conservation outcomes in cropland-impacted protected areas.

Keywords: CBD; area-based targets; conservation; food security; protected areas.

Conflict of interest statement

The authors declare no competing interest.

References

    1. Klein Goldewijk K., Beusen A., Doelman J., Stehfest E.. New anthropogenic land use estimates for the holocene: HYDE 3.2. Earth Syst. Sci. Data. 2017;9:927–953.
    1. Barrett C. B.. Measuring food insecurity. Science. 2010;327:825–828.
    1. Fogel R. W.. The Escape from Hunger and Premature Death, 1700-2100: Europe, America, and the Third World. 2004.
    1. Crist E., Mora C., Engelman R.. The interaction of human population, food production, and biodiversity protection. Science. 2017;356:260–264.
    1. Pimm S. L., Vijay V.. Population, Agriculture, and Biodiversity: Problems and Prospects. 2020;365.

Source: https://pubmed.ncbi.nlm.nih.gov/33468666/?utm_source=no_user_agent&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1zmroqAMnEquTZFTfdGx1V1gPEavo-Be3-FKTecJpOlB7LykCL&fc=20200804213506&ff=20210120135252&v=2.14.2

Continue Reading
News3 days ago

What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?

Uncategorized5 days ago

New York Small Business Cooperative License

Uncategorized5 days ago

New York Cannabis Distributor License

Heartland7 hours ago

MagicMed: Bringing the Drug Candidate Library Model to Psychedelics

Hemp5 days ago

The USDA Has Released Its Final Rule on Hemp Regulation

Uncategorized5 days ago

New York Cannabis Delivery License

Heartland3 days ago

Investors in This Cannabis Stock Are Leaving $800 Million on the Table

Heartland3 days ago

What is Delta-8 THC? Everything You Need to Know

Heartland3 days ago

What’s New With Cannabis Stocks for the Week Ending 01/15/21

Uncategorized5 days ago

Cannabis Nursery in New York

Uncategorized5 days ago

New York’s Marijuana Cultivation License

Heartland4 days ago

Optical Coherence Tomography Findings in Cannabis Users

News5 days ago

CBD News: Clint Eastwood files third suit against CBD companies, saying they’re falsely claiming endorsement

Heartland5 days ago

France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…

Heartland5 days ago

CBD News Roundup: FDA Provides Framework for Future CBD Research

Uncategorized5 days ago

New York’s Adult-Use Processor License

Heartland5 days ago

Airfield Supply Co. And Kiva Confections Launch Breast Cancer Awareness Campaign

Heartland5 days ago

Some Oddly Specific Predictions About Films You Should Keep an Eye Out For This Year

Heartland4 days ago

Antioxidant Function of Phytocannabinoids: Molecular Basis of Their Stability and Cytoprotective Properties under UV-irradiation

Uncategorized5 days ago

New York Cannabis Microbusiness License

Uncategorized5 days ago

New York Cannabis Dispensary License

Heartland5 days ago

Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis

News2 days ago

CBD News: NIHC chairman appointed to board advising U.S. on trade policy

Heartland2 days ago

Alcanna to Spin Out Cannabis Business and Pursue Value Segment Strategy

Heartland2 days ago

Fire & Flower Expands Free Same-Day Delivery Across Its Ontario Network

Heartland2 days ago

Blog – Global Cannabinoids | CBD Wholesale & Bulk | White Label | Private Label

Heartland1 day ago

Hemp & CBD Blog | Northeast Kingdom Hemp

Heartland1 day ago

Informational blogs about CBD and Hemp

Heartland1 day ago

CBD Blog: News, Info & Tips

Heartland2 days ago

Clinical and biochemical heterogeneity of Parkinson’s disease

Trending

A Cloud Nine Capital Entity Copyright © 2020 – All Rights Reserved Proudly Made in America